COR vs. MCK, CAH, DXCM, EW, TAK, IQV, IDXX, CNC, HUM, and MRNA
Should you be buying Cencora stock or one of its competitors? The main competitors of Cencora include McKesson (MCK), Cardinal Health (CAH), DexCom (DXCM), Edwards Lifesciences (EW), Takeda Pharmaceutical (TAK), IQVIA (IQV), IDEXX Laboratories (IDXX), Centene (CNC), Humana (HUM), and Moderna (MRNA). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
Cencora presently has a consensus price target of $218.22, suggesting a potential downside of 8.98%. McKesson has a consensus price target of $533.50, suggesting a potential downside of 1.19%. Given McKesson's stronger consensus rating and higher probable upside, analysts clearly believe McKesson is more favorable than Cencora.
McKesson has a net margin of 0.99% compared to Cencora's net margin of 0.69%. Cencora's return on equity of 323.23% beat McKesson's return on equity.
Cencora has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
In the previous week, McKesson had 24 more articles in the media than Cencora. MarketBeat recorded 31 mentions for McKesson and 7 mentions for Cencora. Cencora's average media sentiment score of 0.54 beat McKesson's score of 0.52 indicating that Cencora is being referred to more favorably in the media.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.5%. Cencora pays out 22.2% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
McKesson received 209 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.05% of users gave McKesson an outperform vote while only 65.03% of users gave Cencora an outperform vote.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.
Summary
McKesson beats Cencora on 13 of the 19 factors compared between the two stocks.
Get Cencora News Delivered to You Automatically
Sign up to receive the latest news and ratings for COR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
